Golden State Equity Partners Sells 550 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Golden State Equity Partners cut its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 19,380 shares of the company’s stock after selling 550 shares during the period. Golden State Equity Partners’ holdings in Mirum Pharmaceuticals were worth $756,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quest Partners LLC increased its position in shares of Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after buying an additional 1,127 shares during the period. Amalgamated Bank grew its holdings in shares of Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares in the last quarter. ProShare Advisors LLC purchased a new position in shares of Mirum Pharmaceuticals during the second quarter worth about $213,000. Finally, Creative Planning purchased a new position in shares of Mirum Pharmaceuticals during the third quarter worth about $249,000.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $39.18 on Thursday. The business has a 50 day moving average of $40.22 and a 200 day moving average of $34.59. The company has a quick ratio of 3.09, a current ratio of 3.28 and a debt-to-equity ratio of 1.34. The company has a market cap of $1.87 billion, a PE ratio of -17.11 and a beta of 1.14. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $45.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The firm had revenue of $77.90 million during the quarter, compared to the consensus estimate of $75.03 million. Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. Mirum Pharmaceuticals’s revenue for the quarter was up 107.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.92) EPS. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MIRM. Leerink Partners upped their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Friday, October 11th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Cantor Fitzgerald upped their target price on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Finally, Evercore ISI boosted their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $56.82.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.